Reports FY25 SG&A expenses $26.1M. “2025 was a pivotal year for Anteris, advancing DurAVR with disciplined execution, strengthening our clinical foundation, and positioning the company for long term leadership in structural heart. We converted strategy into measurable progress, reinforcing our competitive position and accelerating our path toward commercial readiness. The progress achieved in 2025 has strengthened our foundation and sharpened our trajectory toward becoming a leader in next-generation TAVR. We remained focused on what matters most; advancing clinical evidence, strengthening our balance sheet, and building sustainable long-term value,” said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVR:
- Anteris Technologies price target lowered to $17 from $22 at Barclays
- Largest borrow rate increases among liquid names
- Anteris Technologies price target lowered to $15 from $20 at Lake Street
- Anteris Technologies Secures $320 Million for PARADIGM Trial
- Ten new option listings and two option delistings on January 22nd